Showing 10,101 - 10,120 results of 322,654 for search 'AT~', query time: 1.32s Refine Results
  1. 10101
  2. 10102

    A Retrospective Observational Cohort Analysis of Oncology Patients with Febrile Neutropenia in the Emergency Department of a Tertiary Care Hospital in Oman by Badar Al-Aamri, Aisha AL Breiki, Darpanarayan Hazra, Talib Al-Aamri, Manar Al-Shehi

    Published 2025-01-01
    “…High-risk patients exhibited significantly higher rates of positive blood cultures (31.6% vs. 1.6%) and positive urine cultures (20.8% vs. 7.7%). …”
    Get full text
    Article
  3. 10103

    COVID-19-Associated Thrombotic Complication: Is It Pulmonary Embolism or In Situ Thrombosis? by Rashid AL Umairi, Khadija AL Adawi, Maryam AL Khoori, Ahmed AL Lawati, Sachin Jose

    Published 2023-01-01
    “…Out of them, 64 patients had pulmonary embolisms (45 men and 19 women; mean age: 58.4 years with a range of 3698 years). …”
    Get full text
    Article
  4. 10104
  5. 10105
  6. 10106

    Spontaneous Bilateral Hemothorax as a Case of Epithelioid Hemangioendothelioma (EHE) by Essa M. AlGhunaim, Hafsa AlNajem, Derar S. AlShehab

    Published 2019-01-01
    “…Here, we are presenting a case of pleural epithelioid hemangioendothelioma presenting as a case of spontaneous bilateral hemothorax.…”
    Get full text
    Article
  7. 10107

    Unusual Presentation of Gianotti-Crosti Syndrome due to Epstein-Barr Virus Infection by Hind Saif Al Dhaheri, Amani Al Kaabi, Yasmin Kara Hamo, Aysha Al Kaabi, Salwa Al Kaabi, Hossam Al Tatari

    Published 2016-01-01
    “…We report a case of GCS related to EBV infection without the classical systemic symptoms in a five-year-old male patient.…”
    Get full text
    Article
  8. 10108
  9. 10109
  10. 10110

    Crystal structure of catena-poly[diaqua-bis(μ2-4,4′-bipyridyl-κ2N:N′) disilver(I)] 4-oxidopyridine-3-sulfonate trihydrate, C25H29Ag2N5O9S by Zhao Han-Lin, Jiang Jin-Ke, Jiang Hui, Dong Xian-Wu, Li Xue

    Published 2021-09-01
    “…C25H29Ag2N5O9S, monoclinic, P21/m (no. 11), a = 8.5437(16Å, b = 17.852(4Å, c = 9.3335(13Å, β = 101.380(16)°, V = 1395.6(5Å3, Z = 2, Rgt(F) = 0.0271, wRref(F2) = 0.0653, T = 293(2K.…”
    Get full text
    Article
  11. 10111
  12. 10112
  13. 10113
  14. 10114
  15. 10115
  16. 10116
  17. 10117
  18. 10118

    Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial by Clare Robinson, Trudie Chalder, Paul McCrone, Olivier Quintin, Evdoxia Gkaintatzi, Imran Khan, Stephanie J. C. Taylor, on behalf of the SURECAN GROUP

    Published 2025-01-01
    “…Secondary outcomes include scores at 16 and 52 weeks: FACT-G subscales; Fear of Cancer Recurrence Inventory (FCR4); positive and negative Impact of Cancer scales (IOCv2); Hospital Anxiety and Depression scale (HADS); Chalder Fatigue Scale (CFQ); and physical activity, measured on a modified version of the Godin scale. …”
    Get full text
    Article
  19. 10119
  20. 10120